20 results on '"Pierce, Evangeline"'
Search Results
2. 53788 The patient-reported impact of flares on quality of life in pediatric and adolescent patients with moderate-to-severe atopic dermatitis: a real-world study in the United States and Europe.
3. 51219 Lebrikizumab Monotherapy Maintained Improvement of Itch and Sleep-Loss Due to Itch After Two Years in Patients with Moderate-to-Severe Atopic Dermatitis.
4. 50351 Lebrikizumab maintains clinically meaningful outcomes with treatment administered every 4 weeks in adult and adolescent patients with moderate-to-severe atopic dermatitis.
5. 51075 HADS anxiety and depression scores improved in Japanese patients with moderate-to-severe atopic dermatitis following lebrikizumab treatment: 16-week results from a randomized, double-blind, placebo-controlled phase 3 trial (ADhere-J).
6. Lebrikizumab Maintains Improvements in the Patient-Oriented Eczema Measure Through 2 Years of Treatment in Patients With Moderate-to-Severe Atopic Dermatitis.
7. 42136 Lebrikizumab improvement in itch reduction at 52 weeks in patients with moderate-to-severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials.
8. 42152 Efficacy of lebrikizumab in patients who did not achieve protocol defined criteria for response after initial 16 weeks of therapy.
9. 43072 Efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: 16-week results from three randomized Phase 3 clinical trials.
10. 42928 The patient-reported impact of itch and sleep interference on pediatric and adolescent patients with moderate and severe atopic dermatitis: a real-world study in the United States and Europe.
11. 42917 Safety and efficacy of lebrikizumab in adolescent patients with moderate-to-severe atopic dermatitis: an open-label study.
12. 41916 Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials.
13. 41679 Lebrikizumab monotherapy improves quality of life through improvement in itch and sleep: Results from two Phase 3 trials in patients with moderate-to-severe atopic dermatitis.
14. 41915 Improvements in health-related quality of life and psychological symptoms in patients with severe alopecia areata achieving scalp hair regrowth: results from two randomized controlled trials.
15. 33006 Long-term improvement of patient-reported outcomes in adult patients with atopic dermatitis treated with baricitinib in the US and Canada.
16. 33273 Impact of atopic dermatitis lesion locations on patient burden: A real-world study.
17. 33536 Impact of day-to-day sleep disruption on the burden of disease in moderate-severe adult atopic dermatitis patients.
18. 25447 Baricitinib treatment results in clinically meaningful itch reduction and enhanced quality of life in patients with moderate-to-severe atopic dermatitis: Results from BREEZE-AD5.
19. 26670 The contribution of itch and skin severity improvements to the Dermatology Life Quality Index in patients with atopic dermatitis in a baricitinib phase 3 study, BREEZE-AD5.
20. 15058 The effect of baricitinib on daily and workplace activity from phase 3 trials BREEZE-AD1 and BREEZE-AD2 in adult patients with moderate to severe atopic dermatitis.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.